Clinical and serological features of patients with localised scleroderma positive for IgM aCL
| IgM aCL (+) (n=17) | IgM aCL (−) (n=31) | |
|---|---|---|
| Unless otherwise indicated, values are means (SD). | ||
| *p<0.05 and **p<0.01 v patients without IgM aCL. | ||
| Clinical | ||
| Sex (M/F) | 5/12 | 8/23 |
| Age at onset (years) | 21 (17) | 21 (16) |
| Disease duration (years) | 3.2 (4.5) | 5.3 (7.6) |
| No of linear lesions | 1.4 (1.3) | 1.0 (0.9) |
| No of plaque lesions | 5.0 (3.6)** | 1.9 (2.5) |
| Total No of lesions | 6.4 (4.2)** | 2.9 (2.9) |
| No of body areas affected | 3.4 (2.1)* | 2.0 (1.7) |
| Bilateral distribution (%) | 13 (76)** | 8 (26) |
| Muscle involvement (%) | 5 (29) | 5 (16) |
| Serological | ||
| ANA (%) | 15 (88)* | 16 (52) |
| IgM AHA (relative OD) | 0.81 (0.20)** | 0.51 (0.22) |
| IgG AHA (relative OD) | 0.89 (0.23) | 0.74 (0.29) |
| IgG anti-ssDNA (relative OD) | 0.68 (0.28)** | 0.49 (0.18) |
| IgM RF (%) | 10 (59)* | 8 (26) |
| IL6 (pg/ml) | 32.8 (24.5)* | 12.3 (6.9) |